Understanding the Effect of Multiple Sclerosis on General and Dimensions of Mental Health

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Dec 23

PMID 36556099

Authors

Weixi Kang

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of the current study is to investigate how general and dimensions of mental health are affected by multiple sclerosis (MS).

Methods: Factor analysis, generalized linear models, and one-sample t-tests were used to analyze data from 78 people with MS with a mean age of 52.19 (S.D. = 12.94) years old and 25.64% males and 38,516 people without MS with a mean age of 49.10 (S.D. = 18.24) years old and 44.27% males from Understanding Society.

Results: The current study found that there are three underlying factors of the GHQ-12 labeled as GHQ-12A (social dysfunction and anhedonia; 6 items), GHQ-12B (depression and anxiety; 4 items), and GHQ-12C (loss of confidence; 2 items), and the general mental health, GHQ-12A (social dysfunction and anhedonia), and GHQ-12C (loss of confidence) are associated with MS.

Conclusions: Effective mental health management in MS patients is important given mental health in people with MS is linked to the onset of MS and exacerbating disease progression/relapses.

Citing Articles

Association between idiopathic pulmonary fibrosis and risk of different pathological types of lung cancer: a Mendelian randomization study.

Zheng H, Nie D, Huang X J Cancer Res Clin Oncol. 2023; 149(10):7751-7757.

PMID: 37009919 DOI: 10.1007/s00432-023-04727-w.

References

Penninkilampi-Kerola V, Miettunen J, Ebeling H . A comparative assessment of the factor structures and psychometric properties of the GHQ-12 and the GHQ-20 based on data from a Finnish population-based sample. Scand J Psychol. 2006; 47(5):431-40. DOI: 10.1111/j.1467-9450.2006.00551.x. View

Griffith G, Jones K . Understanding the population structure of the GHQ-12: Methodological considerations in dimensionally complex measurement outcomes. Soc Sci Med. 2019; 243:112638. DOI: 10.1016/j.socscimed.2019.112638. View

Mohr D, Hart S, Julian L, Cox D, Pelletier D . Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ. 2004; 328(7442):731. PMC: 381319. DOI: 10.1136/bmj.38041.724421.55. View

White C, White M, Russell C . Invisible and visible symptoms of multiple sclerosis: which are more predictive of health distress?. J Neurosci Nurs. 2008; 40(2):85-95, 102. DOI: 10.1097/01376517-200804000-00007. View

Raissi A, Bulloch A, Fiest K, McDonald K, Jette N, Patten S . Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis. Int J MS Care. 2015; 17(6):292-300. PMC: 4673922. DOI: 10.7224/1537-2073.2014-084. View

Smith A, Fallowfield L, Stark D, Velikova G, Jenkins V . A Rasch and confirmatory factor analysis of the general health questionnaire (GHQ)--12. Health Qual Life Outcomes. 2010; 8:45. PMC: 2873594. DOI: 10.1186/1477-7525-8-45. View

Rossi S, Studer V, Motta C, Polidoro S, Perugini J, Macchiarulo G . Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology. 2017; 89(13):1338-1347. DOI: 10.1212/WNL.0000000000004411. View

Gill S, Santo J, Blair M, Morrow S . Depressive Symptoms Are Associated With More Negative Functional Outcomes Than Anxiety Symptoms in Persons With Multiple Sclerosis. J Neuropsychiatry Clin Neurosci. 2018; 31(1):37-42. DOI: 10.1176/appi.neuropsych.18010011. View

Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdova E, Kesselring J . Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord. 2017; 19:153-160. DOI: 10.1016/j.msard.2017.11.013. View

10.

Silveira C, Guedes R, Maia D, Curral R, Coelho R . Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art. Psychiatry Investig. 2019; 16(12):877-888. PMC: 6933139. DOI: 10.30773/pi.2019.0106. View

11.

Sanchez-Lopez M, Dresch V . The 12-Item General Health Questionnaire (GHQ-12): reliability, external validity and factor structure in the Spanish population. Psicothema. 2008; 20(4):839-43. View

12.

Mohr D, Pelletier D . A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun. 2005; 20(1):27-36. DOI: 10.1016/j.bbi.2005.03.011. View

13.

Mohr D, Hart S, Fonareva I, Tasch E . Treatment of depression for patients with multiple sclerosis in neurology clinics. Mult Scler. 2006; 12(2):204-8. DOI: 10.1191/135248506ms1265oa. View

14.

Murphy R, ODonoghue S, Counihan T, McDonald C, Calabresi P, Ahmed M . Neuropsychiatric syndromes of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2017; 88(8):697-708. DOI: 10.1136/jnnp-2016-315367. View

15.

Parker L, Topcu G, De Boos D, das Nair R . The notion of "invisibility" in people's experiences of the symptoms of multiple sclerosis: a systematic meta-synthesis. Disabil Rehabil. 2020; 43(23):3276-3290. DOI: 10.1080/09638288.2020.1741698. View

16.

Boeschoten R, Braamse A, Beekman A, Cuijpers P, van Oppen P, Dekker J . Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2016; 372:331-341. DOI: 10.1016/j.jns.2016.11.067. View

17.

GRAETZ B . Multidimensional properties of the General Health Questionnaire. Soc Psychiatry Psychiatr Epidemiol. 1991; 26(3):132-8. DOI: 10.1007/BF00782952. View

18.

Fernandes H, Vasconcelos-Raposo J . Factorial validity and invariance of the GHQ-12 among clinical and nonclinical samples. Assessment. 2012; 20(2):219-29. DOI: 10.1177/1073191112465768. View

19.

Briones-Buixassa L, Mila R, Aragones J, Bufill E, Olaya B, Arrufat F . Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress. Health Psychol Open. 2017; 2(2):2055102915612271. PMC: 5193283. DOI: 10.1177/2055102915612271. View

20.

McKay K, Tremlett H, Fisk J, Zhang T, Patten S, Kastrukoff L . Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology. 2018; 90(15):e1316-e1323. PMC: 5894930. DOI: 10.1212/WNL.0000000000005302. View